drugset / Trial / NCT00471471
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with GM-CSF, CpG 7909, and incomplete Freund's adjuvant may make a stronger immune response and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects and how well vaccine therapy works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery.
Timeline
- Start
- 2008-10
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NY-ESO-1 | Protein / enzyme biologic | 100 ug | Subcutaneous |
| Subject | agatolimod | Oligonucleotide (other) | 0.6 mg | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | 80 ug | Subcutaneous |